Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SoftOx Solutions ASFRA:6FV Debt-to-Equity is 0.45 as of Dec. 2025, which is 246% above its 10-year median of 0.13. Among 954 Biotechnology companies, SoftOx Solutions AS ranks worse than 72.12% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for SoftOx Solutions AS's Debt-to-Equity or its related term are showing as below:
FRA:6FV'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.13 Max: 31.28
Current: 0.45
During the past 10 years, the highest Debt-to-Equity Ratio of SoftOx Solutions AS was 31.28. The lowest was 0.04. And the median was 0.13.
FRA:6FV's Debt-to-Equity is ranked worse than 72.12% of 954
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:6FV: 0.45
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
SoftOx Solutions AS Debt-to-Equity Related Terms
SoftOx Solutions AS Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for SoftOx Solutions AS's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6FV vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, SoftOx Solutions AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SoftOx Solutions AS Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SoftOx Solutions AS's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where SoftOx Solutions AS's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SoftOx Solutions AS (FRA:6FV) has a Debt-to-Equity of 0.45 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SoftOx Solutions AS and its competitors. This is 246% above median its historical median of 0.13. Over the past decade, SoftOx Solutions AS's Debt-to-Equity has ranged from 0.04 to 31.28. According to the industry distribution chart, SoftOx Solutions AS ranks #688 out of 954 companies in the Biotechnology industry, placing it in the top 72.1%.
Is SoftOx Solutions AS's Debt-to-Equity too high?
SoftOx Solutions AS's current Debt-to-Equity of 0.45 is 246% above median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 31.28. The Biotechnology industry median Debt-to-Equity is 0.16. SoftOx Solutions AS's value of 0.45 is 181.3% above this industry median. Based on the distribution chart, SoftOx Solutions AS ranks #688 out of 954 companies in the Biotechnology industry, which is below the industry midpoint.
How does SoftOx Solutions AS's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SoftOx Solutions AS ranks #688 out of 954 companies for Debt-to-Equity. This places SoftOx Solutions AS in the lower half of its industry. The industry median Debt-to-Equity is 0.16. SoftOx Solutions AS's value of 0.45 is 181.3% above this benchmark. Historically, SoftOx Solutions AS's own Debt-to-Equity has ranged from 0.04 to 31.28 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 0.16, SoftOx Solutions AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SoftOx Solutions AS's current Debt-to-Equity of 0.45 is 181.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SoftOx Solutions AS and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SoftOx Solutions AS's current Debt-to-Equity is 0.45, which is 246% above median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SoftOx Solutions AS stock overvalued right now?
SoftOx Solutions AS (FRA:6FV) has a current Debt-to-Equity of 0.45. The current Debt-to-Equity is 0.45, which is 246% above median its 10-year median of 0.13 and 181.3% above the Biotechnology industry median of 0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For SoftOx Solutions AS (FRA:6FV), the current Debt-to-Equity is 0.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SoftOx Solutions AS is a clinical-stage pharmaceutical company. It offers antimicrobial solutions for Wound and Skin Care. It has developed an effective antimicrobial solution to combat biofilm, viral, and antimicrobial-resistant infections. The technology is based on extensive research and development in partnership with Nordic research institutes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FV has been successfully added to your 
